Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19
NCT04880109Phase 2Terminated
- Sponsor
- AptaBio Therapeutics Inc.
- Start
- Oct 2021
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of isuzinaxib in coronavirus disease 2019 (COVID-19), sponsored by AptaBio Therapeutics Inc.. Started Oct 2021; status: terminated.
02
Drugs
isuzinaxib
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04880109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04880109.